Wang X,Zhang G,Jiang X,Zhu H,Lu Z,Xu L .2014 .Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. Atherosclerosis, 03(1) : 206-213.
Eslamijouybari M,Heydari K,Maleki I,Moosazadeh M,Hedayatizadeh-Omran A,Vahedi L . .Neutrophil-to-Lymphocyte and Platelet-toLymphocyte Ratios in COVID-19 Patients and Control Group and Relationship with Disease Prognosis. Caspian J Intern Med, 10(Suppl 1) : 531-535.
Forget P,Khalifa C,Defour JP,Latinne D,Van Pel MC,De Kock M. MC,Published MC .2017 .Online 2017 Jan 3. BMC Res Notes, 10 : 12.
Gil H,Magy N,Mauny F,Dupond JL .2003 .Value of eosinopenia in inflammatory disorders: an "old" marker revisited. Rev Med Interne, 8663(03) : 00138-3.
Liu J,Li H,Luo M,Liu J,Wu L,Lin X .2020 .Lymphopenia predicted illness severity and recovery in patients with COVID-19: A singlecentre, retrospective study. PLoS One, 02416(11) : 59.
Liu Y,Du X,Chen J,Jin Y,Peng L,Wang HH,Infect J .2020 .Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. , 04(1) : e6-e12.
Zhang JJ,Dong X,Cao YY,Yuan YD,Yang YB,Yan YQ .2020 .Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. , 10(7) : 1730-1741.
Outh R,Boutin C,Gueudet P,Suzuki M,Saada M,Aumaître H. Eosinopenia M .2020 .<100/μL as a marker of active COVID-19: An observational prospective study. J Microbiol Immunol Infect, 12(1) : 61-68.
Terradas R,Grau S,Blanch J,Riu M,Saballs P,Castells X .2012 .Eosinophil count and neutrophillymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study. PLoS One, 10(8) : .
Holub K,Biete A . .New pre-treatment eosinophilrelated ratios as prognostic biomarkers for survival outcomes in endometrial cancer. 2018 Dec, 10(1) : 1280.
Branicka O,Rogala B,Glück J .2020 .-Lymphocyte Ratios in Various Types of Immediate Hypersensitivity to NSAIDs: A Preliminary Study. Int Arch Allergy Immunol, 10(10) : 774-782.
Anurag A,Jha PK,Kumar A .2020 .Differential white blood cell count in the COVID-19: A crosssectional study of 148 patients. Diabetes Metab Syndr, 10(6) : 2099-2102.
Georgakopoulou VE,Garmpis N,Damaskos C,Valsami S,Dimitroulis D,Diamantis E .2021 .The impact of peripheral eosinophil counts and eosinophil to lymphocyte ratio (ELR) in the clinical course of COVID-19 patients: A retrospective study. In Vivo, 10(1) : 641-8.
Rothenberg ME.,Eosinophilia ME. . .. N Engl J Med. 998 May, 10(22) : 1592-600.
Bass DA,Gonwa TA,Szejda P,Cousart MS,DeChatelet LR,McCall CE . .Eosinopenia of acute infection: production of eosinopenia by chemotactic factors of acute inflammation. J Clin Invest. 1980 Jun, 1(6) : 1265-71.
Cortés-Vieyra R,Gutiérrez-Castellanos S,Álvarez -Aguilar C,Baizabal-Aguirre VM,Nuñez-Anita RE,Rocha-López AG . .Behavior of eosinophil counts in recovered and deceased COVID-19 patients over the course of the disease. Viruses. 2021 Aug, 10(9) : 1675.
Roca E,Ventura L,Zattra CM,Lombardi C. .2021 .EOSINOPENIA: an early, effective and relevant COVID-19 biomarker?. QJM, 10(1) : 68-69.
Rafai WA,Ussaid A,Riaz B,Baig FA,Anwar S,Masood A .2022 .Correlation of hematological findings with severity of. COVID-19. Med Res Arch, 10(5) : 2740-13.
Tanni F,Akker E,Zaman MM,Figueroa N,Tharian B,Hupart KH .2020 .Eosinopenia and COVID19. J AM Osteopath Assoc, 120(8) : 504-8.
Soni M. .2021 .Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. Int J Lab Hematol, 10(Suppl 1) : 137-41.
Henry BM,De Oliveira MH,Benoit S,Plebani M,Lippi G .2020 .Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 10(7) : 1021-8.
Waris A,Din M,Khalid A,Abbas Lail R,Shaheen A,Khan N .2021 .Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan's experience. J Clin Lab Anal, 10(6) : .
Jemaa AB,Salhi N,Othmen MB,Ali HB,Guissouma J,Ghadhoune H,Immunopharmacol Int .2022 .Evaluation of individual and combined NLR, LMR and CLR ratio for prognosis disease severity and outcomes in patients with COVID-19. , 108781 : 108781.